Kiniksa Pharmaceuticals (NASDAQ:KNSA) PT Raised to $30.00 at Evercore ISI

Kiniksa Pharmaceuticals (NASDAQ:KNSA) had its target price raised by investment analysts at Evercore ISI from $25.00 to $30.00 in a report released on Wednesday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Evercore ISI’s target price would indicate a potential upside of 70.36% from the company’s current price.

KNSA has been the topic of a number of other reports. TheStreet upgraded Kiniksa Pharmaceuticals from a “d+” rating to a “c” rating in a research note on Thursday, February 29th. Wedbush restated an “outperform” rating and set a $30.00 price target on shares of Kiniksa Pharmaceuticals in a research note on Tuesday.

Kiniksa Pharmaceuticals Stock Down 1.4 %

NASDAQ:KNSA opened at $17.61 on Wednesday. The stock’s fifty day moving average is $19.32 and its two-hundred day moving average is $18.00. Kiniksa Pharmaceuticals has a 52 week low of $10.65 and a 52 week high of $22.09. The stock has a market capitalization of $1.24 billion, a price-to-earnings ratio of 160.11 and a beta of 0.27.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, April 23rd. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.11). Kiniksa Pharmaceuticals had a negative return on equity of 7.32% and a net margin of 2.78%. The firm had revenue of $79.90 million for the quarter, compared to analyst estimates of $76.97 million. During the same quarter last year, the company earned ($0.18) earnings per share. The firm’s revenue for the quarter was up 65.4% on a year-over-year basis. On average, sell-side analysts expect that Kiniksa Pharmaceuticals will post -0.06 EPS for the current fiscal year.

Insider Activity

In other news, CAO Michael R. Megna sold 5,126 shares of the stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $21.79, for a total value of $111,695.54. Following the sale, the chief accounting officer now directly owns 17,588 shares in the company, valued at $383,242.52. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Kiniksa Pharmaceuticals news, CAO Michael R. Megna sold 5,126 shares of the firm’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $21.79, for a total value of $111,695.54. Following the sale, the chief accounting officer now directly owns 17,588 shares in the company, valued at $383,242.52. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Michael R. Megna sold 9,659 shares of the firm’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $21.45, for a total value of $207,185.55. Following the completion of the sale, the chief accounting officer now owns 17,588 shares in the company, valued at $377,262.60. The disclosure for this sale can be found here. Over the last three months, insiders have sold 33,109 shares of company stock worth $709,929. Corporate insiders own 54.23% of the company’s stock.

Institutional Trading of Kiniksa Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. raised its stake in Kiniksa Pharmaceuticals by 349.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,097 shares of the company’s stock valued at $72,000 after buying an additional 3,186 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in Kiniksa Pharmaceuticals by 59.9% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 256,932 shares of the company’s stock valued at $4,463,000 after buying an additional 96,288 shares in the last quarter. Principal Financial Group Inc. acquired a new stake in Kiniksa Pharmaceuticals in the third quarter valued at $777,000. Linden Thomas Advisory Services LLC raised its stake in Kiniksa Pharmaceuticals by 100.0% in the third quarter. Linden Thomas Advisory Services LLC now owns 115,891 shares of the company’s stock valued at $2,013,000 after buying an additional 57,942 shares in the last quarter. Finally, Alps Advisors Inc. raised its stake in Kiniksa Pharmaceuticals by 38.3% in the third quarter. Alps Advisors Inc. now owns 71,103 shares of the company’s stock valued at $1,235,000 after buying an additional 19,709 shares in the last quarter. 53.95% of the stock is currently owned by institutional investors and hedge funds.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.